vs
Empire State Realty Trust, Inc.（ESRT）とPacira BioSciences, Inc.（PCRX）の財務データ比較。上の社名をクリックして会社を切り替えられます
Empire State Realty Trust, Inc.の直近四半期売上が大きい（$190.3M vs $177.4M、Pacira BioSciences, Inc.の約1.1倍）。Pacira BioSciences, Inc.の純利益率が高く（1.6% vs 1.6%、差は0.1%）。Empire State Realty Trust, Inc.の前年同期比売上増加率が高い（5.7% vs 5.0%）。過去8四半期でEmpire State Realty Trust, Inc.の売上複合成長率が高い（0.2% vs -0.2%）
エンパイア・ステート・リアルティ・トラストは、ニューヨーク都市圏を中心にオフィス、小売店舗、住宅などの優良不動産を所有・運用する不動産投資信託で、象徴的なエンパイアステートビルもポートフォリオに含みます。持続可能な運用を通じ長期的な資産価値の向上を目指しています。
Pacira BioSciences社は非オピオイド系疼痛管理ソリューションの開発・商業化に特化した専門製薬企業で、主に米国の病院や外来手術センターなどの医療機関に術後鎮痛向け製品を提供し、一部海外市場への展開も進めています。
ESRT vs PCRX — 直接比較
損益計算書 — Q1 FY2026 vs Q1 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $190.3M | $177.4M |
| 純利益 | $3.0M | $2.9M |
| 粗利率 | — | — |
| 営業利益率 | 15.5% | 3.9% |
| 純利益率 | 1.6% | 1.6% |
| 売上前年比 | 5.7% | 5.0% |
| 純利益前年比 | -73.7% | — |
| EPS（希薄化後） | $0.20 | $0.07 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | $190.3M | $177.4M | ||
| Q4 25 | $199.2M | $196.9M | ||
| Q3 25 | $197.7M | $179.5M | ||
| Q2 25 | $191.3M | $181.1M | ||
| Q1 25 | $180.1M | $168.9M | ||
| Q4 24 | $197.6M | $187.3M | ||
| Q3 24 | $199.6M | $168.6M | ||
| Q2 24 | $189.5M | $178.0M |
| Q1 26 | $3.0M | $2.9M | ||
| Q4 25 | $32.2M | — | ||
| Q3 25 | $13.6M | $5.4M | ||
| Q2 25 | $11.4M | $-4.8M | ||
| Q1 25 | $15.8M | $4.8M | ||
| Q4 24 | $18.8M | — | ||
| Q3 24 | $22.8M | $-143.5M | ||
| Q2 24 | $28.6M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | 15.5% | 3.9% | ||
| Q4 25 | 17.8% | 1.2% | ||
| Q3 25 | 19.9% | 3.5% | ||
| Q2 25 | 18.4% | 4.7% | ||
| Q1 25 | 14.3% | 1.2% | ||
| Q4 24 | 21.7% | 13.2% | ||
| Q3 24 | 22.7% | -82.8% | ||
| Q2 24 | 20.8% | 15.9% |
| Q1 26 | 1.6% | 1.6% | ||
| Q4 25 | 16.1% | — | ||
| Q3 25 | 6.9% | 3.0% | ||
| Q2 25 | 6.0% | -2.7% | ||
| Q1 25 | 8.8% | 2.8% | ||
| Q4 24 | 9.5% | — | ||
| Q3 24 | 11.4% | -85.1% | ||
| Q2 24 | 15.1% | 10.6% |
| Q1 26 | $0.20 | $0.07 | ||
| Q4 25 | $0.11 | $0.05 | ||
| Q3 25 | $0.05 | $0.12 | ||
| Q2 25 | $0.04 | $-0.11 | ||
| Q1 25 | $0.05 | $0.10 | ||
| Q4 24 | $0.07 | $0.38 | ||
| Q3 24 | $0.08 | $-3.11 | ||
| Q2 24 | $0.10 | $0.39 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $68.8M | $144.3M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $1.8B | $653.9M |
| 総資産 | $4.4B | $1.2B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | $68.8M | $144.3M | ||
| Q4 25 | $132.7M | $238.4M | ||
| Q3 25 | $154.1M | $246.3M | ||
| Q2 25 | $94.6M | $445.9M | ||
| Q1 25 | $187.8M | $493.6M | ||
| Q4 24 | $385.5M | $484.6M | ||
| Q3 24 | $421.9M | $453.8M | ||
| Q2 24 | $535.5M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $1.8B | $653.9M | ||
| Q4 25 | $1.1B | $693.1M | ||
| Q3 25 | $1.0B | $727.2M | ||
| Q2 25 | $1.0B | $757.8M | ||
| Q1 25 | $1.0B | $798.5M | ||
| Q4 24 | $1.0B | $778.3M | ||
| Q3 24 | $1.0B | $749.6M | ||
| Q2 24 | $1.0B | $879.3M |
| Q1 26 | $4.4B | $1.2B | ||
| Q4 25 | $4.5B | $1.3B | ||
| Q3 25 | $4.1B | $1.3B | ||
| Q2 25 | $4.1B | $1.5B | ||
| Q1 25 | $4.1B | $1.6B | ||
| Q4 24 | $4.5B | $1.6B | ||
| Q3 24 | $4.4B | $1.5B | ||
| Q2 24 | $4.4B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ESRT
| Rental revenue (1) | $166.1M | 87% |
| Observatory revenue | $18.5M | 10% |
| Other revenue and fees | $4.1M | 2% |
| Lease termination fees | $1.4M | 1% |
| Third-party management and other fees | $277.0K | 0% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
